Risk factor
Very poor trading liquidity
Profitability factor
Solid dividends
About
Cosmo Bio Company, Limited is a key player in the life science research sector, involved in the global import, export, manufacturing, marketing, and distribution of essential biotools. Their extensive product line includes biochemical reagents, specialized kits, scientific instruments, analytical software, and diagnostic products. Among their research reagents, they offer a wide spectrum such as antibodies, antigens, bioactive substances, enzymes, peptides, amino acids, various chemicals, carbohydrates, lipids, and components derived from viruses and bacteria. They also provide crucial detection reagents, cell and tissue culture systems, and gene analysis solutions. In terms of instrumentation, Cosmo Bio supplies electrophoresis apparatuses, cell culture labware, gene manipulation systems, and data analysis software. Beyond products, the company delivers valuable services like drug discovery support, custom research, and clinical diagnostics. A significant part of their operation involves the development and manufacturing of proprietary cell and cell culture products. This includes a range of specialized cells such as adipose tissue, bone, cartilage, tooth, pancreas, liver function, cardiovascular, immune, and mesenchymal stem cells, in addition to feeder cells, tumor cell lines, coating reagents, and macrophage-related products. They also produce various assay kits for measurement, staining, detection, and purification. Furthermore, they offer specialized biotechnology research equipment, including constant-temperature transport containers, aluminum block heat insulation devices, and dew condensation prevention glass plates, alongside consigned services for custom peptide synthesis and antibody production. Serving a diverse clientele of laboratories, research institutes, and life science education and testing organizations, Cosmo Bio distributes its products through its own outlets in Japan and an international network of sales agents. The company was founded in Tokyo, Japan, in 1978, where its headquarters remain.
Company Valuation
Considering past and projected metrics, the stock is slightly 'cheaper' than its peers. In particular, the stock is reasonably priced on P/E, of fair value on EV/EBITD.